LAS VEGAS, June 26, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it is continuing to expand its broad worldwide patent portfolio in support of its proprietary product development programs. The U.S. Patent office has notified Samaritan that it has issued Patent No. 7,056,694 to Samaritan's research collaborator Georgetown University, and Samaritan holds the worldwide exclusive license for this patent through its collaboration.
http://www.samaritanpharma.com/html/patents.html
The issued patent identifies peripheral-type benzodiazepine receptor associated proteins, such as PAP7, and its ability to interact with and regulate the function of the peripheral-type benzodiazepine receptor, a key mitochondrial protein involved in steroid biosynthesis, cell proliferation, cancer progression, and Alzheimer's disease pathology.
Eugene Boyle, CFO of Samaritan stated, "Our clinical and scientific programs continue to generate an expanding array of new patent developments and this patent represents yet another milestone in Samaritan's intellectual property strategy."
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech company, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on our Website so we can notify you of upcoming conference calls, news and events.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.